Evidence map›Paper›PMID 34854748›Full record

Trial reportThe Journal of urology2022

One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume

Sean P Elliott, Karl Coutinho, Kaiser J Robertson, Richard D'Anna, Kent Chevli, Serge Carrier, Melanie Aube-Peterkin, Christopher H Cantrill, Michael J Ehlert, Alexis E Te and 14 more

2 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03499964 naactive not recruitingnot on this map

ROBUST III - Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease - A Randomized Control Trial

TypeinterventionalSponsorUrotronic Inc.Ran2018 to 2026Enrolled127ConditionsUrethral StrictureArmsOptilume Drug Coated Balloon (DCB), Control Treatment
NCT06827210 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Treatment of Bulbar Urethral Strictures With Optilume Drug-Coated Balloons in an Untreated Population

TypeinterventionalSponsorAalborg University HospitalRan2025 to 2027Enrolled140ConditionsUrethral Stricture, Urethral Stricture, Anterior, Urethral Stricture, Male, Urethral Stricture Less Than 2 cmArmsOptilume DCB, Standard Direct Visual Internal Urethrotomy (DVIU)
3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Outcomes of patients undergoing OptilumeWorld journal of urology · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Sean P ElliottUniversity of Minnesota, Minneapolis, Minnesota.
Karl CoutinhoNew Jersey Urology LLC, Millburn, New Jersey.
Kaiser J RobertsonChesapeake Urology, Hanover, Maryland.
Richard D'AnnaArkansas Urology, Little Rock, Arkansas.
Kent ChevliWestern New York Urology Associates, Cheektowaga, New York.
Serge CarrierMcGill University Health Center, Montreal, Quebec, Canada.
Melanie Aube-PeterkinMcGill University Health Center, Montreal, Quebec, Canada.
Christopher H CantrillUrology San Antonio, San Antonio, Texas.
Michael J EhlertMetro Urology, a division of Minnesota Urology, Woodbury, Minnesota.
Alexis E TeWeill Cornell Medicine, New York, New York.
Jeffrey DannAdvanced Urology Institute, Daytona Beach, Florida.
Jessica M DeLongUrology of Virginia PLLC, Virginia Beach, Virginia.
Steven B BrandesColumbia University, New York, New York.
Judith C HagedornUniversity of Washington, Seattle, Washington.
Richard LevinChesapeake Urology Research Associates, Annapolis, Maryland.
Amy SchlaiferAcademic Urology & Urogynecology of Arizona, Phoenix, Arizona.
Euclid DeSouzaAdult and Pediatric Urology PC, Omaha, Nebraska.
David DiMarcoOregon Urology Institute, Springfield, Oregon.
Brad A EricksonUniversity of Iowa Hospitals and Clinics, Iowa City, Iowa.
Richard NataleCarolina Urology Partners PLLC, Concord, North Carolina.
Douglas A HusmannMayo Clinic, Rochester, Minnesota.
Allen MoreyUT Southwestern Medical Center, Dallas, Texas.
Carl OlssonIntegrated Medical Professionals, New York, New York.
Ramón VirasoroUrology of Virginia PLLC, Virginia Beach, Virginia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe Optilume® drug-coated balloon (DCB) is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III study is a randomized, single-blind trial evaluating the safety and efficacy of the Optilume DCB against endoscopic management of recurrent anterior urethral strictures. MATERIALS AND

methodsEligible patients were adult males with anterior strictures ≤12Fr in diameter and ≤3 cm in length, at least 2 prior endoscopic treatments, International Prostate Symptom Score ≥11 and maximum flow rate <15 ml per second. A total of 127 subjects were enrolled at 22 sites. The primary study end point was anatomical success (≥14Fr by cystoscopy or calibration) at 6 months. Key secondary end points included freedom from repeat treatment, International Prostatic Symptom Score and peak flow rate. The primary safety end point included freedom from serious device- or procedure-related complications.

resultsBaseline characteristics were similar between groups, with subjects having an average of 3.6 prior treatments and average length of 1.7 cm. Anatomical success for Optilume DCB was significantly higher than control at 6 months (75% vs 27%, p <0.001). Freedom from repeat intervention was significantly higher in the Optilume DCB arm. Immediate symptom and urinary flow rate improvement was significant in both groups, with the benefit being more durable in the Optilume DCB group. The most frequent adverse events included urinary tract infection, post-procedural hematuria and dysuria.

conclusionsThe results of this randomized controlled trial support that Optilume is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures <3 cm in length. The Optilume DCB may serve as an important alternative for men who have had an unsuccessful direct vision internal urethrotomy/dilation but want to avoid or delay urethroplasty.

Indexed as

AdultCoated Materials, BiocompatibleDilatationHumansMaleMiddle AgedPaclitaxelProspective StudiesRecurrenceSingle-Blind MethodTreatment OutcomeUrethral StrictureCoated Materials, BiocompatiblePaclitaxellower urinary tract symptomsurethral strictureurinary bladder neck obstruction

Identifiers

PMID34854748
PMCPMC12721643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.